Events & Presentations

Amy Raskopf, Evofem's SVP of Investor Relations, spoke with Matthew Dunahoo on the MarketGems Podcast about:

• Women's health; 
• Phexxi^® (lactic acid, citric acid and potassium bitartrate), Evofem's hormone-free, local-acting, on-demand contraceptive; 
• The interaction between GLP1s and oral birth control pills, why women concurrently using these drugs may be at higher risk for unintended pregnancy, and how using Phexxi during certain four-week intervals in the GLP-1 dosing regimen can reduce this risk; and,
• The latest on the proposed merger with Aditxt, Inc. (Nasdaq: ADTX)

Listen in!